Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-07-05

Clinical Trial Update: Treadmill Cardiovascular Safety Study of Erenumab (AMG 334) [Phase 2]

View source ↗

Summary

Phase 2 treadmill cardiovascular safety study of erenumab (AMG 334) completed in patients with stable angina; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • erenumab (erenumab)

Snippet

Sponsor: Amgen | Conditions: Stable Angina | Phase 2 | Status: COMPLETED | Results posted: 2018-07-05